Diabetes Core Update – December 2018
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment set...
Source: Diabetes Core Update - December 26, 2018 Category: Endocrinology Authors: American Diabetes Association Source Type: podcasts
Diabetes Core Update – January 2018
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment set...
Source: Diabetes Core Update - December 26, 2018 Category: Endocrinology Authors: American Diabetes Association Source Type: podcasts
Dapagliflozin: 'Helpful Strategy' for T1D?
Research presented at EASD 2017 shows that dapagliflozin may reduce insulin requirements with a low risk of adverse effects in patients with type 1 diabetes. (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - October 20, 2017 Category: Endocrinology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
On June 14, 2016, FDA strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (brand names Invokana, Invokamet) and dapagliflozin (brand names Farxiga, Xigduo XR). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 21, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
The Lancet: June 25, 2010
Professor Cliff Bailey discusses the potential role of dapagliflozin for the treatment of type 2 diabetes. (Source: Listen to The Lancet)
Source: Listen to The Lancet - June 25, 2010 Category: General Medicine Authors: The Lancet Source Type: podcasts
